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Allogeneic islet transplantation is a promising approach for restoring normoglycemia in type 1 diabetic patients. Current use of
immunosuppressive therapies for management of islet transplant recipients can be counterintuitive to islet function and can lead
to complications in the long term. The induction of donor-speciﬁc tolerance eliminates the dependency on immunosuppression
and allows recipients to retain responses to foreign antigens. The mechanisms by which tolerance is achieved involve the deletion
of donor-reactive T cells, induction of T-cell anergy, immune deviation, and generation of regulatory T cells. This review will
outline the various methods used for inducing donor-speciﬁc tolerance in islet transplantation and will highlight the previously
unforeseen potential of tissue stromal cells in promoting islet engraftment.
1.Introduction
Diabetes mellitus is a disease characterized by metabolic
abnormalities and the onset of hyperglycemia, which results
from dysregulation of insulin. Insulin promotes the entry of
glucose from the blood into the tissues. Diabetes aﬀects ap-
proximately 25.8 million people of all ages, with the preva-
lence rising with age. Long-term complications of diabetes
include nephropathy, retinopathy, neuropathy, and athero-
sclerosis [1]. The type II variant, or noninsulin-dependent
form, arises from a resistance to insulin or inadequate pro-
duction of insulin by the pancreatic β islets, eventually
leading to islet dysfunction and desensitization to glucose.
Type II diabetes accounts for 90–95% of all diagnosed
cases of diabetes [1]. The current management for type II
diabetes involves a change in lifestyle—weight loss and
dietarymodiﬁcations—andadministrationofglucosereduc-
ing agents. Type I diabetes, the more severe form of diabetes,
aﬀects 5% of the population [1] and results from autoim-
mune destruction of the pancreatic β islets. Since the islets
fail to produce insulin altogether, the only treatment options
for type I diabetes are exogenous delivery of insulin and
pancreas or islet transplantation.
Despite improvements in the administration of insulin
delivery and insulin supplying devices, maintenance of
adequate and steady glucose levels with exogenous insulin
therapy alone can be challenging and can cause episodes
of hypoglycemia. Diabetic patients with suboptimal control
of glycemia ultimately develop long-term complications.
Currentlytheonlyreal“cure”fortypeIdiabetesistransplan-
tation of the pancreas or isolated islets, which would result in
insulin production closer to physiological conditions.
However, pancreas transplantation is generally consid-
ered only for severe, late-stage diabetics and is a signiﬁcant
surgical procedure requiring extensive immunosuppression
[2–4]. Islet transplantation is, therefore, a more feasible al-
ternative to pancreas transplantation. In comparison, islet
transplantation has lower risks of morbidity and mortality
and greater opportunities for in vitro manipulations of
islets to optimize engraftment. The concept of transplanting
pancreatic fragments to reverse diabetes was ﬁrst proposed
by the English surgeon Watson Williams in 1893 [5].
However,lackofknowledgeaboutimmunerejectionandim-
munosuppression at the time prevented progress [2]. It was
not until 1967 that Lacy and Ballinger demonstrated the ﬁrst
real advancement in islet transplantation. Using a rodent
model in which recipients of islet allografts were induced to
develop type I diabetes by administration of streptozotocin
(STZ),mimickingautoimmunedestructionofthepancreatic
islets, Kemp et al. demonstrated that pancreatic islet cell2 International Journal of Endocrinology
transplants could restore metabolic control and prevent
long-term complications [6].
Translation from rodent to larger animal and human
models had been hampered by diﬃculties in islet isolation
from the pancreas, the lack of quality of isolated islets,
and route of administration [7, 8]. The development of
an automated method for human islet cell processing by
Ricordi et al. in 1986 [9] and the discovery that islet clusters
could be heterotopically implanted into the liver contributed
to the ﬁrst successful allogeneic islet transplantation in
humans in 1989 by Lacy et al. [6, 10, 11]. Nevertheless,
success rates remained low with only 10% of patients
achieving insulin independence for greater than a year and
demonstrating islet allograft rejection and recurrence of
autoimmunity. Poor clinical outcomes were attributed to
insuﬃcient numbers of islets being transplanted and an
ineﬀective immunosuppression regimen [12].
2. ImmuneResponse to the Graft
The alloresponse is largely a T-cell-mediated response to
the major histocompatibility complex molecules (MHCs)
on the surface of donor tissues. Antigen presenting cells
(APCs), such as dendritic cells (DCs), process and present
donor peptides and molecules through MHCs to recipient
T cells by the indirect pathway. Additionally, recipient T
cells can recognize donor antigen directly on the surface of
inﬁltrating donor-derived APCs through the direct pathway.
T-cell receptors (TCR) on the surface of the recipient T cells
recognize the peptide-MHC complex, initiating signaling
cascades and activation of the T cells. In addition to this
primary signal, additional interactions through costimula-
tory molecules on the T cells and APCs are required for full
activation of the T cells. Upon activation, the T cells promote
a series of proinﬂammatory events and initiate the activation
of other cell types resulting in recruitment of leukocytes and
humoral factors to the graft. The eﬀector response includes
the production of the cytokines IFN-γ and IL-2 by type 1
helper (Th1) CD4+ T cells, the cytotoxic factors granzyme
and perforin by CD8+ T cells, and alloantibodies (Abs) by B
cells [13].
3. Pitfalls of Immunosuppression
Current immunosuppressive therapies target T cells since
they are the main culprits in rejection. Previously, the stan-
dard protocol for immunosuppression for islet transplan-
tation consisted of a combination of calcineurin inhibitors
(tacrolimusandcyclosporine),purineanalogs(mycophenol-
atemofetil),andcorticosteroids.Manyoftheseagentsproved
to be diabetogenic, impairing insulin secretion, and lethal to
the islets [14]. The advent of the Edmonton protocol in 1999
was a signiﬁcant step in the ﬁeld of islet transplantation.
The Edmonton protocol utilized a steroid-free therapy
based on low-dose sirolimus, tacrolimus, and daclizumab
(a humanized anti-IL-2 receptor α mAb). Furthermore, the
protocol administered two infusions of islets from diﬀerent
donors to increase chances of engraftment. All 7 patients
involved in the trial demonstrated insulin independence
beyond 1 year [15, 16]. Despite the success of rapamycin-
based therapies, they have their own shortcomings including
increased risk of hyperlipidemia, hypertension, and pneu-
monia [15]. Work by Monti et al. reported that patients
conditioned under the Edmonton protocol receiving infu-
sionofcadavericisletsdevelopedlymphopeniaanddisplayed
elevatedserumlevelsofhomeostaticcytokines,leadingtothe
expansion of autoreactive cells [17].
While the results of multiple center clinical trials demon-
strated that the protocol can provide short-term insulin
independence and reduce incidences of acute rejection, the
patients regressed back to insulin dependency, and graft
function was lost in several patients within 5 years [18].
Chronic administration of immunosuppression of any kind
will eventually lead to risk of infection, malignancies, and
drug toxicity [19]. Maintenance immunosuppression can,
therefore, be detrimental rather than beneﬁcial to trans-
plant recipients. Side eﬀects of immunosuppression often
outweigh the beneﬁts of islet transplantation.
The risks associated with immunosuppressive agents
prompted investigation into tolerance inducing therapies,
with the goal being to achieve indeﬁnite graft survival with-
out dependency on long-term immunosuppression while
preserving host immunity to other alloantigens. Tolerance
induction has been challenging in both large animal and
human models due to the complex nature of the allore-
sponse. Tolerance at both the central and peripheral stages
involves clonal deletion of alloreactive T-cells, T cell anergy,
immune deviation, and induction of regulatory T cells.
4. Central Tolerance
Central tolerance refers to lack of responsiveness to self
through deletion of self-reactive T cells in the thymus—the
site of T-cell maturation and selection [20]. Donor-speciﬁc
tolerance can be achieved using strategies similar to those
used for preventing autoimmunity. Intrathymic tolerance
(IT) can be induced by intrathymic inoculations of recipient
APCspulsedwithallopeptides.Alloantigens,whenpresented
in the context of self-APCs result in donor-speciﬁc unre-
sponsiveness and promote tolerance. However, the clinical
applications of the IT model face many challenges as it is
an invasive technique and may have limited potential in
adults, since the thymus involutes with age, compromising
the tolerance process [21, 22].
An alternative and perhaps more eﬀective method
for achieving central tolerance involves the generation of
hematopoietic chimerism, which is developed through bone
marrow (BM) transplantation. Prospective transplant recip-
ients are conditioned with total body irradiation (TBI) or
partial myeloablation prior to BM transplantation in order
to make room for the transplanted bone marrow. BM cell
transplantation enables the reconstitution of the recipient
hematopoieticcompartmentwithdonorhematopoieticstem
cells. Donor-reactive T cells are then deleted through centralInternational Journal of Endocrinology 3
regulation and maintained by peripheral mechanisms. The
use of TBI for prolonging islet allograft survival was orig-
inally proposed by Britt et al. [23] and later shown by
other groups to prevent the onset of diabetes in nonobese
diabetic (NOD) mice [24]. Though combined islet and
hematopoietic cell transplant seems promising, the inherent
risksassociatedwiththeprocesshavelimiteditsapplications.
TBI or myeloablation prior to receipt of the BM increases
the risk of infection and malignancies. Additionally, BM
transplantation is met with the risk of graft versus host
disease (GVHD) [25, 26]. Mixed allogeneic chimerism is
emerging as a safer method to fully allogeneic chimerism.
Mixed chimerism can be achieved in allogeneic BM recipi-
ents conditioned with sublethal total body irradiation with
the aid of costimulatory blockade or anti-CD4 and anti-
CD8 monoclonal (m)Abs [27–29]. NOD mice receiving
nonmyeloablativeconditioningacceptedallogeneicisletsand
displayed a reversal of autoimmunity, suggesting successful
establishment of mixed chimerism [30]. Similarly, NOD
mice that received low-dose irradiation, cyclophosphamide
(CY), and two intravenous infusions of BM from WT mice
showed high levels of donor-cell chimerism and eﬀectively
eliminated host donor-reactive lymphocytes after transfer of
splenocytes from overtly diabetic NOD mice [31, 32]. BM
infusion at the time of islet transplantation may, therefore,
be used to induce donor-speciﬁc tolerance to islet allografts.
5. Tolerance through T-Cell
Depletion Strategies
Another strategy in promoting tolerance involves the deple-
tion of alloreactive CD4+ and CD8+ T cells prior to trans-
plantation. Depletion of alloreactive T cells would promote
a hyporesponsive environment and peripheral mechanisms
of anergy, thus driving the shift towards tolerance [33, 34].
Depletion can be achieved through TBI, lymphocyte deplet-
ingAbs,andpharmaceuticalagents.Anti-CD3mAbhasbeen
used for development of mixed chimerism in murine NOD
models with few side eﬀects, achieving the same results as
myeloablation while bypassing the risk of GVHD [35, 36].
Anti-CD3 mAb is proposed to downmodulate the TCR
complex, induce apoptosis of alloreactive T cells, increase
production of the immunoregulatory cytokine TGF-β,a n d
promotethedevelopmentofregulatoryTcells[37,38].Anti-
CD3 is eﬀective in inducing tolerance in models of both
syngeneicandallogeneicislettransplantation,enablinglong-
term engraftment [34, 39]. Antithymocyte globulin (ATG)
is also a potent inducer of T-cell depletion. Its mechanisms
of action are poorly understood, though. Administration of
ATG alone or in combination with other agents prolonged
allograft survival in various models [40–43]. Islet allograft
survival was signiﬁcantly improved in a nonhuman primate
model with administration of ATG and the B-cell-depleting
CD20 mAb, rituximab [44]. Taken together these ﬁndings
suggest that lymphoid-depleting agents may not be eﬀective
as a monotherapy but may be useful in combination with
other tolerance-inducing therapies.
6. Tolerance Induction through
Costimulatory Blockade
Tolerance can also be achieved by interfering with costimu-
latory interactions to inhibit the secondary signal required
for full T-cell activation. Suboptimal signaling renders the
cells anergic. The B7-CD28 pathway is a key pathway in T-
cell activation, survival, and function. Blockade of the B7
(CD80, CD86) receptor on APCs with CD28 on T cells mod-
ulates the immune response. In rodent models, B7-CD28
blockadethroughadministrationofinhibitoryCTLA4-Igled
to prolonged allograft survival and tolerance [45–48]. In
nonhuman primates, however, CTLA-Ig treatment alone led
to moderate improvements in allograft survival but failed to
induce tolerance [47–49].
Similar ﬁndings have been reported with CD40-CD154
blockade. Ligation of the CD40 receptor on APCs with CD40
ligand (CD154) on T cells enhances TCR signaling and
eﬀector responses [50, 51]. CD154-deﬁcient mice displayed
impaired antigen-speciﬁc T-cell responses and priming.
Coadministrationofanti-CD154mAbandinactivateddonor
lymphocytes resulted in long-term survival of islet allo-
grafts in an STZ-induced rodent model and nonhuman
primate models with pancreatectomy [7, 52, 53]. Anti-
CD154 mAb downregulated CD28 on donor lymphocytes,
thereby inhibiting CD28-CD80 interactions between donor
APCs and recipient T cells [54]. Anti-CD154 mAb treatment
has been shown to result in “indeﬁnite” survival in islet, BM,
and cardiac allograft models [53, 55–57].
Whether true tolerance can be achieved with anti-CD154
mAb alone or in combination with BM transplantation,
donor-speciﬁc transfusion (DST), or conventional immuno-
suppression is debatable. Anti-CD154 mAb therapy is met
with mixed results. Kenyon et al. reported that rhesus
monkeys treated with the humanized anti-CD154 mAb
(hu5c8) prior to transplantation with periodic maintenance
therapy achieved long-term survival and improved function
of intrahepatic islet allografts with little to no side eﬀects [7].
In contrast, Kirk et al., using a similar regimen, found that
while hu5c8 therapy prevented acute renal allograft rejection
in rhesus monkeys, recipients developed donor-speciﬁc Abs
and showed signs of chronic allograft nephropathy [58]. A
similar result has been reported by Azimzadeh et al. using a
primate cardiac allograft model [59]. Although anti-CD154
mAb therapy may allow for the manipulation of donor-
speciﬁc responses and assist in the induction of tolerance,
the consequences of administering anti-CD154 mAb need to
be evaluated further. There are strong indications that anti-
CD154 mAb therapy results in thromboembolic complica-
tions in nonhuman primate models [60]. Discrepancies in
outcomes may be due to timing of administration, dosage,
duration, and dependent on the animal model.
7. DCs in Tolerance
DCs play a critical role in provoking the immune response
by mediating the uptake, processing, and presentation of
antigen from the microenvironment to naive T cells in4 International Journal of Endocrinology
the secondary lymphoid tissues. However, DCs also act as
regulators in the thymus and periphery by eliminating self-
reactive T cells and preventing autoimmunity [21]. There-
fore, DCs may be key to achieving central and peripheral
tolerance by helping shape the immune response. The
immunogenic versus tolerogenic nature of DCs is dependent
on the maturation of the DCs and the subset. Manipulation
of DCs may, therefore, serve as a therapeutic tool in the
design of tolerogenic regimens [61, 62]. Murine DC subsets
are characterized and categorized based on their surface
markers and origin, such as myeloid DCs (CD11c+CD8 α+,
CD11c+CD8 α−), plasmacytoid (p)DCs (CD11c−B220+Gr-
1+), and Langerhans cell-derived DCs from the epidermis
(CD11c−). Human DCs fall primarily into two categories:
monocytes and pDCs (CD4+CD8−CD11c−). Diﬀerences in
murine and human DC surface markers make comparisons
diﬃcult [63].
Whereas mature myeloid DCs upregulate MHC class II
and the costimulatory molecules CD40, CD80, and CD86,
immature DCs downregulate these markers and are potent
inhibitors of allospeciﬁc T-cell responses [64]. The lack of
stimulatory molecules allows immature DCs to induce anti-
gen speciﬁc hyporesponsiveness in T cells [65]. Immature
DCs also vary in their stimulatory activity. CD11b+CD8 α−
DCs induce a Th2 phenotype (IL-4, IL-5, IL-10, and IL-
13), while CD11b−CD8 α+ DCs induce a Th1 phenotype
(IL-2 and IFN-γ) through secretion of IL-12 [63, 66]. In
addition to skewing the Th1/Th2 proﬁle, tolerogenic DCs
have been shown to promote allograft acceptance by deletion
and anergy of alloreactive T cells and induction of donor-
speciﬁc regulatory T (Treg) cells [67–69].
The ability of tolerogenic DCs to mediate anergy and
proliferative arrest of alloreactive T cells has been demon-
strated by Munn et al. pDCs produce indoleamine 2,3-
dioxygenase (IDO), which catabolizes the essential amino
acid L-tryptophan, and triggers the integrated stress path-
way within antigen speciﬁc T cells and suppresses their
proliferation and function [70]. The exact mechanism by
which these tolerogenic DCs inhibit alloreactive T cells is
not well understood but is thought to involve the activation
of the general control nondepressible-2 (GCN2) kinase
pathway. The GCN2 pathway is activated in response to an
accumulation of uncharged tRNAs that results from amino
aciddeprivation[71].TransferoftolerogenicIDOproducing
immature DCs from primary tolerant recipients into murine
cardiac allograft recipients enhanced allogeneic T cell apop-
tosis and Treg-cell development resulting in prolonged graft
survival [67]. Ochando et al. showed that treatment with
DST and anti-CD154 mAb prompted pDCs to migrate to the
allograft and subsequently induced Treg development in the
lymph nodes. Furthermore, pDCs isolated from tolerogenic
mice promoted CD4+CD25−Foxp3− T cells to convert into
CD4+CD25+Foxp3+ Treg cells in vitro [72].
DC maturation can be limited through addition of
cytokines (IL-10 and TGF-β) and costimulatory blockade
[73, 74]. In mice, BM cells cultured in the presence of gran-
ulocyte macrophage colony-stimulating factor (GM-CSF)
alonetendedtoacquireanimmaturephenotype—expressing
low levels of MHC class II and costimulatory molecules.
In contrast, addition of IL-4 to the GM-CSF culture led
t oD Cm a t u r a t i o na n dh i g hl e v e l so fM H Cc l a s sI I ,C D 4 0 ,
CD80, and CD86 expression [75–77]. DCs can be restricted
to an immature state through pharmacological interventions
as well. In vitro, rapamycin conditioned BM-derived DCs
suppressed the development of alloreactive CD4+ T cells but
allowed for the proliferation and functioning of Tregs [78].
Lutz et al. examined the tolerogenic potential of immature
myeloid DCs and found that the transfer of these immature
myeloid DCs induced a state of T-cell unresponsiveness and
resulted in a signiﬁcant improvement in cardiac allograft
survival [75].
In addition to extrinsic inﬂuences, DC maturation is also
governed by NF-κb signaling. NF-κb regulates expression
of MHCs and costimulatory molecules. Lu et al. inhibited
NF-κb activity within DCs by constructing a decoy double-
stranded oligodeoxynucleotide (ODN) that selectively inhib-
ited expression of costimulatory molecules while permitting
the expression of MHCs, thus preventing DC matura-
tion. Genetic engineering of DCs allows for expression of
molecules that play a role in the inhibition of T-cell
responses. Administration of DCs deﬁcient in NF-κba c t i vi t y
preventedtheonsetofdiabetesinNODmice[79].Recipients
of virally transduced DCs expressing CTLA4-Ig, IL-10,
or FasL displayed improved pancreatic islet and cardiac
allograft survival [80–83]. The therapeutic potential of these
engineered DCs is limited by the fact that the cells may
become activated or mature in vivo through exposure to the
virus and proinﬂammatory stimuli [80].
8.Myeloid-DerivedSuppressorCells
(MDSCs) in Tolerance
MDSCs are emerging as important regulators of toler-
ance. Originally identiﬁed for their role as suppressors in
cancer [84, 85], MDSCs are comprised of heterogeneous
myeloid cell populations: subsets of DCs, macrophages, and
granulocytes. MDSCs in mice are characterized based on
expression of the markers CD11b, Gr-1, Ly6C, and Ly6G.
MDSCs can be divided even further by their nuclear mor-
phology as mononuclear, monocytic MDSCs (CD11b+Gr-
1highLy6G−Ly6Chigh) and polymorphonuclear, granulocytic
MDSCs (CD11b+Gr-1intLy6G+Ly6Clow)[ 86]. Their variabil-
ity can even be extended to their function and produc-
tion of immunosuppressive components arginase-1 (Arg-1),
inducible nitric oxide synthase (iNOS), and reactive oxygen
species (ROS), with suppressive function depending on the
environment and pathological condition [87–89]. MDSCs
make up a relatively small proportion in healthy mice but
expand and accumulate in the lymphoid tissue of tumor
bearing mice, remaining in an immature state and inhibiting
antitumor responses [90, 91]. The generation and expansion
of MDSCs is dependent on inﬂammatory cues [92, 93]. The
inﬂammatory molecules vascular endothelial growth factor
(VEGF) and GM-CSF have been linked to the accumulation
of MDSCs [94, 95]. Additional proinﬂammatory cytokines
IL-1β and IL-6 have been shown to contribute to the
development of MDSCs. IL-1β secreting tumors had greaterInternational Journal of Endocrinology 5
accumulation of MDSCs with improved lifespan resulting in
aggressive tumor growth [96–98].
The ability of MDSCs to suppress T-cell responses
and expand Treg cells has been demonstrated in various
models of autoimmunity, infection, and cancer [99–101].
The mechanisms by which MDSCs impart their suppressive
eﬀect include production of iNOS and arginase-1. Arginase-
1 depletes L-arginine resulting in downregulation of the
TCRζ chain and inhibition in production of cell cycle reg-
ulator proteins [102, 103]. iNOS promotes phosphorylation
of the Janus kinase 3 and STAT5 pathway and inhibits
MHC class II expression and T-cell proliferation [104–
106]. MDSCs also produce ROS and peroxynitrates, which
inhibit protein tyrosine phosphorylation through nitration
of tyrosine residues [88, 107]. Increased production of these
factors was observed in tumor models and related to T-cell
unresponsiveness [108].
As suggested in tumor models, MDSCs may be use-
ful in transplant settings by suppressing alloreactive T-
cell responses and prolonging graft survival. In a murine
kidney allograft model, Dugast et al. demonstrated that
recipients with long-term surviving grafts exhibited an
accumulation of CD3−MHC II−CD11b+CD80/86+ cells in
the blood and graft. Isolation and characterization of the
cells revealed myeloid-like morphology. These cells showed
strong suppressive activity against activated T cells, with
suppressive activity related to the increased number of cells
and dependent on production of iNOS. The phenotypic
and functional analysis of these cells ﬁts the criteria for
MDSCs. Inhibition of the MDSC suppressor molecule iNOS
by aminoguanidine resulted in rejection of kidney allografts
[109].MDSCsalsohaveimplicationsinskintransplantmod-
els. Heme oxygenase-1 (HO-1) secreting MDSCs facilitated
tolerance in recipients of skin allografts through T-cell sup-
pression and IL-10 production [110]. Our group has recently
shown that cotransplantation of MDSCs with islet allografts
reduces CD8+ eﬀector T-cell responses and results in the
expansion of antigen speciﬁc Tregs in the draining lymph
nodes (dLNs), spleen, and peripheral blood, translating to
markedly improved islet allograft survival. MDSC-mediated
suppressor functions were dependent on the inhibitory B7-
H1 (PD-L1)-PD1 pathway. The protective eﬀect imparted by
Tregs was negated in recipients receiving B7-H1−/− MDSCs.
Frequencies of CD4+Foxp3+ cells were markedly reduced
in all compartments in B7-H1−/− MDSC recipients. Direct
evidence for the role of B7-H1 in MDSC-induced Treg
development was demonstrated through in vitro coculture of
donor BALB/C T cells with DCs or MDSCs from WT or B7-
H1−/− MDSCs. WT MDSCs expanded Foxp3+ cells, whereas
MDSCs deﬁcient in B7-H1 exhibited reduced capacity for
Treg induction. Further evidence was shown in B6 mice
intravenously injected with OVA-speciﬁc CD4+ T cells with
subsequent footpad injection of OVA-pulsed WT or B7-
H1−/− MDSCs. Examination of the popliteal LNs showed an
increase in the frequency of CD4+Foxp3+ cells in recipients
of OVA-pulsed WT MDSCs compared to recipients of OVA-
pulsed B7-H1−/− MDSCs. Therefore, it appears that MDSCs
require B7-H1 to exert their immunoregulatory activity and
to induce Tregs [111, 112].
9. Tregs in Tolerance
The presence of CD4+CD25+Foxp3+ regulatory T cells is
correlated with improved graft outcomes and tolerance
[113–116]. Tregs act as surveillance for the immune system,
and depletion of Tregs results in lymphoproliferation and
autoimmune syndrome [117–119]. Biopsies taken from
grafts of tolerant recipients had greater inﬁltration of Tregs
compared to those from rejecting grafts [120]. While Treg
cells only make up 5–10% of the mature T-cell population,
they are potent in numbers [121]. Lymphodepletional
therapies and costimulatory blockades alone can do little
in terms of promoting tolerance; therefore, strategies that
promote Treg cells and their functions will improve chances
of engraftment. Unfortunately, many immunosuppressive
agents, especially those targeting the IL-2 receptor and IL-2,
inhibit Treg development and function since IL-2 signaling
is critical to T cell survival and proliferation [122]. The
ideal scenario would minimize immunosuppressive therapy
and focus on expanding the endogenous Treg population
or generation of antigen-speciﬁc Tregs, thereby inducing
tolerance without the need for immunosuppression.
There is evidence that apoptotic cells have the ability to
inﬂuence Treg development by way of DCs [123]. Apoptotic
cells suppress inﬂammatory responses by emitting inhibitory
signalstoDCsandotherphagocytes.Adopttransferofdonor
apoptotic cells imparted an immature phenotype on DCs,
which in turn inhibited CD4+ T cell activation and IL-
2a n dI F N - γ production. Combination with CD40-CD154
blockade led to prolonged cardiac allograft survival through
induction of Tregs [124].
It is speculated that Tregs impart their suppressive func-
tion through direct interactions with cells (engagement with
CTLA4-Ig), production of soluble factors and inhibitory
cytokines TGF-β and IL-10, and cytokine deprivation [125,
126]. Zhang et al. [127] provided mechanistic insight into
how Tregs exert their suppressive eﬀect using an islet
allograft model. Tregs in the blood migrated to the allograft
through the guidance of the chemokines CCR2, CCR4, and
CCR5. Upon activation, they traveled to the dLNs where
they inhibited DC migration and antigen-speciﬁc T-cell
migrationandresponseinthedLNsandisletallografts[127].
Similar observations were made by Golshayan et al. Alloanti-
gen speciﬁc Tregs were expanded in vitro and maintained
their suppressive function in vivo. When transferred into
recipients of skin allografts, they traﬃcked to the secondary
lymphoid organs and accumulated in the graft dLNs and
within the allograft itself. The donor-speciﬁc Tregs delayed
graft rejection in the absence of immunosuppression. Tregs
inﬁltrated skin allografts early on in the immune response
and suppressed rejection by inhibiting alloreactive T-cell
responses. In the presence of Tregs, CD4+ T cells produced
far less IFN-γ and did not accumulate in the secondary lym-
phoid tissues [113] .T h es u p p r e s s i v ef e a t u r e so fT r e g sm a k e
them candidates for therapeutic use in islet transplantation.
The diﬀerential eﬀects of immunosuppressive therapies
on Treg development make it diﬃcult to determine the opti-
mal combination of agents that promote Treg activity, while
inhibiting Teﬀ functions. Transient depletion of dividing T6 International Journal of Endocrinology
cells with anti-CD25 mAb altered the homeostatic balance
and created space for de novo expansion of Tregs. Anti-
CD25 mAb recipients displayed tolerance to islet allografts,
unlike control-treated recipients [128]. These data suggest
that not all T-cell depleting therapies may have an eﬀect on
Tregs or that Tregs may adapt by downregulating CD25. In
contrast, Li et al. showed that anti-CD25 mAb treatment
preventedtoleranceofliverallograftsbyreducingtheratioof
CD4+CD25+ Tregs to CD3+ T cells [129]. The Teﬀ/Treg ratio
determines the outcome of the graft; therefore, expansion of
Treg populations and deletion of eﬀector T-cell populations
are crucial to tolerance induction. Zheng et al. have shown
that combined treatment of rapamycin and agonistic IL-
2/Fc and antagonistic mutant IL-15/Fc selectively targeted
alloreactive T cells while preserving Tregs [130]. When
administered with other calcineurin inhibitors, beneﬁcial
eﬀects were lost [122, 131, 132] .T h u s ,n o ta l la g e n t swi t h i na
family necessarily exert the same eﬀect.
One of the current limitations of Treg therapy is the
inability to generate suﬃcient numbers of antigen-speciﬁc
Tregs for therapeutic outcomes. The absence of reliable
markers for human Tregs makes isolation and puriﬁcation
diﬃcult. Isolated T cells would have to be expanded in vitro,
but expansion may not be restricted to Treg populations
speciﬁcally. Additionally, Tregs demonstrate a great degree of
plasticity and have the potential of converting to an eﬀector
phenotype in vivo [133]. The risks associated with Treg
therapy warrant further investigation and require technical
advancement before application in humans.
10. Organ Stromal Cellsin Tolerance
The contribution of organ stromal cells in the regulation
of the immune response is understudied. Our group has
extensively investigated the inﬂuence of these populations in
the liver on islet transplantation. The liver is unique in that
it is one of few organs with inherent tolerogenic properties
[134–136]. A number of factors have been attributed to the
tolerogenic state of liver allografts including increased B-
cell inﬁltration, production of soluble MHC class I antigens,
involvement from stromal cells, and presence of Tregs [112,
137–139].Theimportanceofliverstromalcellsishighlighted
by the fact that while liver transplantation in mice results
in indeﬁnite acceptance, transplantation of hepatocytes is
rejected [140, 141].
We have focused on a population of stromal cells in the
liver called the hepatic stellate cells (HSCs), which have been
known to have a primary role in liver ﬁbrosis and repair
following hepatic injury. Additional features of these cells
are their participation in the storage of vitamin A (retinoid)
droplets, and their ability to produce TGF-β in response to
inﬂammation [142–144]. However, little is known about the
involvement of HSCs in immune regulation. HSCs, from
both mice and humans, have been shown to act as nonpro-
fessional APCs and upregulate MHCs, CD40 and CD80, and
inhibitory PD-L1, in response to proinﬂammatory cytokines
[137, 139]. Jiang et al. found that HSCs can also expand
CD4+CD25+Foxp3+ cells in an IL-2-dependent manner
[145]. Therefore, it is conceivable that these cells possess
tolerogenic qualities. Addition of HSCs into an MLR culture
at an HSC to T ratio of 1:20 resulted in 80–90% inhibition
of T-cell response [137]. In vivo inhibition was demonstrated
in mice by cotransplantation of HSCs with islet allografts.
A prolongation in survival in >60% of islet allografts was
observed without immunosuppression. This was associated
with elimination of antigen-speciﬁc T cells and enhanced
MDSC and Treg development [112, 146, 147]. It appears
that HSCs exert their eﬀects primarily by inducing MDSCs.
The ability of HSCs to promote MDSCs was veriﬁed in vivo
by analyses of mononucleocytes inﬁltrating the islet grafts.
Cotransplantation with HSCs led to an accumulation of
MDSCs, instead of DCs, as seen in islet alone grafts. In vitro
evidence conﬁrmed that addition of HSCs to BM-derived
DC culture promoted the development of CD11b+CD11−c
cells displaying suppressive functions. MDSC induction
was abolished in IFN-γ−/− recipients, demonstrating the
additional dependency of an inﬂammatory environment for
MDSC development [112, 146]. MDSCs have been shown to
induce Treg development as well [148]. Increased Treg levels
were observed with islet/HSC transplantation. We, therefore,
suspect that HSCs recruit MDSCs to the islet allografts
and promote engraftment upon inﬂammation. Benten et
al. have shown the tolerogenic role of HSCs in promoting
hepatic engraftment in a rat hepatic allograft model. Hepatic
transplantation led to the activation of HSCs and a series
of genetic and phenotypic changes within the HSCs. Prior
depletion of HSCs impaired hepatocyte acceptance [149].
HSCs demonstrate potent immunomodulatory properties
and can inﬂuence the development of suppressor cells. With
further study, HSCs may be implemented into tolerance
inducing therapies.
Analogous to HSCs, Sertoli cells (SCs) within the
seminiferous tubules of the testis also exhibit suppressive
features. The immunoprivileged SCs have been exploited for
protection of various transplanted tissues [150–154]. The
immunoprotective capabilities of SCs can be extended across
allogeneic and xenogeneic barriers [155, 156]. Transplan-
tation of SC xenografts alone into NOD mice altered the
cytokine milieu in the pancreas and induced a regulatory
environment, inhibiting IL-6, IL-10, and IFN-γ produc-
tion while promoting TGF-β and the regulatory enzyme
indoleamine. TGF-β produced by the SCs was responsible
for the generation of autoantigen-speciﬁc regulatory T cells.
Recipients displayed reversion of diabetes with the SC
xenografts [157]. It has also been shown that SCs have
the ability to inﬂuence and inhibit T-cell responses and
complement activation, although the mechanisms are not
well deﬁned [158–160]. Selawry et al. were the ﬁrst group
to demonstrate the application of the immunomodulatory
SCs for inducing tolerance in islet transplantation [158, 161,
162]. Cotransplantation of SCs and islet allografts induced
long-term graft survival, with recipients remaining normo-
glycemic for at least 60 days after transplantation without
systemic immunosuppression [150, 157]. The transfer of
xenogenic neonatal porcine SCs (NPSCs) at the time of islet
transplantation was shown to prolong islet allograft survival
in nonimmunosuppressed rats in a dose-dependent mannerInternational Journal of Endocrinology 7
(MST=16.33±1.53daysversusisletsalonegroup,5.67±0.94
days). Examination of grafts showed reduced lymphocyte
inﬁltration and increased expression of Bcl-2 compared to
recipients receiving islets alone, suggesting that NPSCs may
also be regulating the expression of immunoprotective genes
[163]. There is also evidence that NPSCs can suppress the
upregulation of CD40 expression on DCs in response to LPS
stimulation, thereby preventing full activation of the DCs
andinducingthedevelopmentoftolerogenicDCs[160].The
eﬃcacy of NPSCs has even been demonstrated in human
models of xenotransplantation. Transplantation of porcine
islets and NPSCs into type 1 diabetic patients led to a reduc-
tion in insulin dependence and maintenance of metabolic
control for up to 4 years without immunosuppression in half
of the 12 patients involved in the study [164]. Cotransfer of
SCs at the time of transplantation may, therefore, provide
protection for alloislet transplants and improve chances of
engraftment.
The BM also contains a rich source of immunomodu-
latory stromal cells referred to as mesenchymal stem cells
(MSCs). MSCs have the capacity to develop into various
types of mesodermal tissues and exhibit properties of self-
renewal [165]. MSCs alter the cytokine proﬁle of DCs,
naive and eﬀector T cells, and NK cells in response to
IFN-γ, downregulating the production of IFN-γ and TNF-α
in the microenvironment and inducing a more tolerogenic
phenotype. IFN-γ-induced expression of the immunosup-
pressive factors TGF-β, hepatic growth factor (HGF), IL-10,
prostaglandin E2, matrix metalloproteinases (MMPs), and
IDO account for the inhibition of alloresponses [166–168].
Furthermore, MSCs were found to promote the expansion
of Tregs [169–171]. Characterization of human MSCs has
been a challenge, and the results are somewhat conﬂicting
[165, 172]. Fiorina et al. found that in their NOD model,
murine bone-marrow-derived MSCs were positive for the
stem cell markers CD29, CD44, CD73, CD105, and CD166
and negative for hematopoietic lineage markers CD45 and
CD90.2 and costimulatory molecules CD40, CD80, and
CD86. Interestingly, the MSCs expressed high levels of PD-
L1, and it was speculated that the level of PD-L1 expression
enabled the immunosuppressive functions of MSCs [169].
The ability of MSCs to modulate T-cell responses and
inﬂuence tissue rejection suggests a therapeutic role for
inducing tolerance in islet transplantation. The negligi-
ble expression of MHC II and absence of costimulatory
molecules on the cell surface allow MSCs to escape immune
recognition. However, the immunomodulatory eﬀects of
MSCsobservedinvitrohavebeendiﬃculttoreplicateinvivo,
asevidencedinbaboonskinallograftandratcardiacallograft
models [173, 174]. Allogeneic MSC infusion has been eﬀec-
tive in preventing the onset of diabetes in prediabetic mice
and reversing hyperglycemia in diabetic mice [169, 175]. In
islet transplantation models, MSCs demonstrate the ability
to migrate to the pancreatic islets and exert an immuno-
suppressive eﬀect in the graft microenvironment [176,
177]. MSCs have also been shown to inﬂuence pancreatic
vascularization and remodeling following transplantation
[178]. Although the mechanisms by which MSCs exert their
immunosuppressiveeﬀectsremainelusive,Dingetal.suggest
that one possible strategy involves the production of MMP-2
and MMP-9. In culture, MSCs mediated T-cell proliferative
arrest and hyporesponsiveness by downregulating CD25
on the surface of T cells. Downregulation of CD25 was
dependent on the production of MMP-2 and MMP-9 by
MSCs, since inhibition of MMP via the thiirane gelatinase
inhibitor SB-3CT restored surface expression of CD25 and
T-cell responses. Administration of syngeneic MSCs at the
time of syngeneic islet transplantation prevented rejection
in murine STZ-induced diabetic Rag-2/γ(c)KO recipients
reconstituted with CD4+CD25− Tc e l l sa n dr e s u l t e di na
rapid return to normoglycemia. In contrast, recipients under
the same conditions treated with the MMP-2 and MMP-9
inhibitor SB-3CT became diabetic within 30 days (MST =
30 days) [167]. In theory, MSC therapies sound promising
in the induction of tolerance but require further evaluation
before clinical application.
11. Concluding Remarks
The future of islet transplantation depends on the devel-
opment of tolerance inducing therapies. While temporary
immunosuppression can be advantageous, the long-term
risks outweigh the beneﬁt. Tolerance suggests freedom from
insulin dependency and an improvement in the patient’s
overall quality of life. A tolerizing regimen that utilizes
techniques that selectively target donor-reactive T cells while
expanding populations of regulatory T cells will result
in better outcomes. Further investigation into inherently
tolerogenic cells in the body such as HSCs, SCs, and MSCs
will aid in the design of therapies. Though many challenges
still remain, the progress made in the animal models of
tolerance holds great promise for humans.
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